Quarterly report · Q3

Period2022-04-01 → 2022-12-31
Filed2023-02-10
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥175.2bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥62.5bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Revenue¥208.2bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥154.2bn2021-04-01 → 2021-12-31Cons.Revenue IFRS
Revenue¥56.5bn2021-10-01 → 2021-12-31dCons.Revenue IFRS
Operating income¥58.7bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥22.4bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Operating income¥84.6bn2021-04-01 → 2021-12-31Cons.Operating profit loss IFRS
Operating income¥22.7bn2021-10-01 → 2021-12-31dCons.Operating profit loss IFRS
Profit before tax¥60.2bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥22.2bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Profit before tax¥96.2bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥85.2bn2021-04-01 → 2021-12-31Cons.Profit loss before tax IFRS
Profit before tax¥22.9bn2021-10-01 → 2021-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥39.3bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥15.2bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥63.8bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥56.2bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥15.4bn2021-10-01 → 2021-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥41.8bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥15.9bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Net income¥58.5bn2021-04-01 → 2021-12-31Cons.Profit loss IFRS
Net income¥15.8bn2021-10-01 → 2021-12-31dCons.Profit loss IFRS
Total assets¥380.7bnat 2022-12-31Cons.Assets IFRS
Total assets¥346.0bnat 2022-03-31Cons.Assets IFRS
Total assets¥324.8bnat 2021-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥83.4bnat 2022-12-31Cons.Liabilities IFRS
Total liabilities¥82.0bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥297.4bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥264.0bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥252.7bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥207.3bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥290.7bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥257.8bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥246.6bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥109.8bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥104.3bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥95.3bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥89.1bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥33.4bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥52.1bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥31.0bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥8.6bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥23.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥10.1bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥20.7bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥16.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥15.6bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥57.862022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥22.422022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥94.062021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥82.752021-04-01 → 2021-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥22.662021-10-01 → 2021-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥57.822022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥22.42022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥93.982021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥82.682021-04-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥22.642021-10-01 → 2021-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio76.4%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio74.5%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.9%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 107
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥3.9bn
Reconciling Itemsreconcilingrevenue2022-10-01 → 2022-12-31−¥1.1bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥3.9bn
Reconciling Itemsreconcilingrevenue intersegment2022-10-01 → 2022-12-31−¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-10-01 → 2022-12-31−¥418m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2022-04-01 → 2022-12-31¥11.5bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2022-10-01 → 2022-12-31¥3.1bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2022-04-01 → 2022-12-31¥10.8bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2022-10-01 → 2022-12-31¥2.9bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥623m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥178m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2022-04-01 → 2022-12-31¥4.2bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2022-10-01 → 2022-12-31¥734m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2022-04-01 → 2022-12-31¥20.6bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2022-10-01 → 2022-12-31¥6.6bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2022-04-01 → 2022-12-31¥20.1bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2022-10-01 → 2022-12-31¥6.4bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥521m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥174m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2022-04-01 → 2022-12-31¥6.0bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2022-10-01 → 2022-12-31¥1.8bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2022-04-01 → 2022-12-31¥69.8bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2022-10-01 → 2022-12-31¥27.2bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2022-04-01 → 2022-12-31¥67.4bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2022-10-01 → 2022-12-31¥26.5bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥2.4bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥739m
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2022-04-01 → 2022-12-31¥32.1bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2022-10-01 → 2022-12-31¥13.3bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2022-04-01 → 2022-12-31¥47.3bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2022-10-01 → 2022-12-31¥17.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2022-04-01 → 2022-12-31¥47.2bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2022-10-01 → 2022-12-31¥17.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥21m
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥17m
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2022-04-01 → 2022-12-31¥13.9bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2022-10-01 → 2022-12-31¥5.8bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2022-04-01 → 2022-12-31¥27.5bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2022-10-01 → 2022-12-31¥8.8bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2022-04-01 → 2022-12-31¥27.2bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2022-10-01 → 2022-12-31¥8.8bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥304m
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2022-04-01 → 2022-12-31¥3.2bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2022-10-01 → 2022-12-31¥917m
—segment totalrevenue2022-04-01 → 2022-12-31¥176.6bn
—segment totalrevenue2022-10-01 → 2022-12-31¥62.7bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥172.8bn
—segment totalrevenue external2022-10-01 → 2022-12-31¥61.6bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥3.8bn
—segment totalrevenue intersegment2022-10-01 → 2022-12-31¥1.1bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥59.5bn
—segment totalsegment profit2022-10-01 → 2022-12-31¥22.6bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥3.7bn
Reconciling Itemsreconcilingrevenue2021-10-01 → 2021-12-31−¥1.2bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥3.7bn
Reconciling Itemsreconcilingrevenue intersegment2021-10-01 → 2021-12-31−¥1.2bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥1.3bn
Reconciling Itemsreconcilingsegment profit2021-10-01 → 2021-12-31−¥803m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2021-04-01 → 2021-12-31¥11.0bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2021-10-01 → 2021-12-31¥2.8bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2021-04-01 → 2021-12-31¥10.6bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2021-10-01 → 2021-12-31¥2.7bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥465m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2021-10-01 → 2021-12-31¥102m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2021-04-01 → 2021-12-31¥4.0bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2021-10-01 → 2021-12-31¥582m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2021-04-01 → 2021-12-31¥16.2bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2021-10-01 → 2021-12-31¥6.1bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2021-04-01 → 2021-12-31¥15.5bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2021-10-01 → 2021-12-31¥5.8bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥710m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2021-10-01 → 2021-12-31¥227m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2021-04-01 → 2021-12-31¥3.8bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2021-10-01 → 2021-12-31¥1.8bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2021-04-01 → 2021-12-31¥64.7bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2021-10-01 → 2021-12-31¥26.3bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2021-04-01 → 2021-12-31¥62.7bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2021-10-01 → 2021-12-31¥25.6bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥2.0bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2021-10-01 → 2021-12-31¥674m
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2021-04-01 → 2021-12-31¥30.8bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2021-10-01 → 2021-12-31¥14.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2021-04-01 → 2021-12-31¥37.9bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2021-10-01 → 2021-12-31¥13.5bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2021-04-01 → 2021-12-31¥37.8bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2021-10-01 → 2021-12-31¥13.5bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥17m
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2021-10-01 → 2021-12-31¥5m
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2021-04-01 → 2021-12-31¥41.5bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2021-10-01 → 2021-12-31¥3.4bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2021-04-01 → 2021-12-31¥25.7bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2021-10-01 → 2021-12-31¥8.2bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2021-04-01 → 2021-12-31¥25.2bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2021-10-01 → 2021-12-31¥8.0bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥438m
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue intersegment2021-10-01 → 2021-12-31¥200m
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2021-04-01 → 2021-12-31¥4.6bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2021-10-01 → 2021-12-31¥2.0bn
—segment totalrevenue2021-04-01 → 2021-12-31¥155.4bn
—segment totalrevenue2021-10-01 → 2021-12-31¥56.8bn
—segment totalrevenue external2021-04-01 → 2021-12-31¥151.8bn
—segment totalrevenue external2021-10-01 → 2021-12-31¥55.6bn
—segment totalrevenue intersegment2021-04-01 → 2021-12-31¥3.6bn
—segment totalrevenue intersegment2021-10-01 → 2021-12-31¥1.2bn
—segment totalsegment profit2021-04-01 → 2021-12-31¥84.7bn
—segment totalsegment profit2021-10-01 → 2021-12-31¥21.8bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 789
ItemContextValueUnit
Impairment losses reversal of impairment losses ope cf IFRSPrior1YTDDuration-JPY
Impairment losses reversal of impairment losses ope cf IFRSCurrentYTDDuration-820000000JPY
Loss gain on sale of shares of subsidiaries ope cf IFRSPrior1YTDDuration-1236000000JPY
Loss gain on sale of shares of subsidiaries ope cf IFRSCurrentYTDDuration-JPY
Gain relating to loss of control over subsidiaries ope cf IFRSPrior1YTDDuration-9443000000JPY
Gain relating to loss of control over subsidiaries ope cf IFRSCurrentYTDDuration-JPY
Loss gain on change in equity ope cf IFRSPrior1YTDDuration-21906000000JPY
Loss gain on change in equity ope cf IFRSCurrentYTDDuration-JPY
Finance income ope cf IFRSPrior1YTDDuration-593000000JPY
Finance income ope cf IFRSCurrentYTDDuration-1561000000JPY
Finance costs ope cf IFRSPrior1YTDDuration42000000JPY
Finance costs ope cf IFRSCurrentYTDDuration46000000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSPrior1YTDDuration336000000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSCurrentYTDDuration-1299000000JPY
Loss gain on valuation of financial assets measured at fair value through profit or loss ope cf IFRSPrior1YTDDuration-13000000JPY
Loss gain on valuation of financial assets measured at fair value through profit or loss ope cf IFRSCurrentYTDDuration-285000000JPY
Decrease increase in trade and other receivables ope cf IFRSPrior1YTDDuration-8048000000JPY
Decrease increase in trade and other receivables ope cf IFRSCurrentYTDDuration-3515000000JPY
Increase decrease in trade and other payables ope cf IFRSPrior1YTDDuration2385000000JPY
Increase decrease in trade and other payables ope cf IFRSCurrentYTDDuration158000000JPY
Increase decrease in provisons for customer loyalty program ope cf IFRSPrior1YTDDuration534000000JPY
Increase decrease in provisons for customer loyalty program ope cf IFRSCurrentYTDDuration-335000000JPY
Decrease increase in other current assets ope cf IFRSPrior1YTDDuration-23000000JPY
Decrease increase in other current assets ope cf IFRSCurrentYTDDuration-1620000000JPY
Other changes in working capital ope cf IFRSPrior1YTDDuration-1239000000JPY
Other changes in working capital ope cf IFRSCurrentYTDDuration-1724000000JPY
Subtotal ope cf IFRSPrior1YTDDuration50543000000JPY
Subtotal ope cf IFRSCurrentYTDDuration54632000000JPY
Interest and dividends received ope cf IFRSPrior1YTDDuration1254000000JPY
Interest and dividends received ope cf IFRSCurrentYTDDuration976000000JPY
Interest paid ope cf IFRSPrior1YTDDuration-42000000JPY
Interest paid ope cf IFRSCurrentYTDDuration-45000000JPY
Income taxes refund paid ope cf IFRSPrior1YTDDuration-20782000000JPY
Income taxes refund paid ope cf IFRSCurrentYTDDuration-22176000000JPY
Net cash provided by used in operating activities IFRSPrior1YTDDuration30972000000JPY
Net cash provided by used in operating activities IFRSCurrentYTDDuration33387000000JPY
Payments into time deposits inv cf IFRSPrior1YTDDuration-20180000000JPY
Payments into time deposits inv cf IFRSCurrentYTDDuration-12585000000JPY
Proceeds from withdrawal of time deposits inv cf IFRSPrior1YTDDuration15689000000JPY
Proceeds from withdrawal of time deposits inv cf IFRSCurrentYTDDuration23021000000JPY
Purchase of financial assets measured at fair value inv cf IFRSPrior1YTDDuration-838000000JPY
Purchase of financial assets measured at fair value inv cf IFRSCurrentYTDDuration-1306000000JPY
Proceeds from sale of financial assets measured at fair value inv cf IFRSPrior1YTDDuration247000000JPY
Proceeds from sale of financial assets measured at fair value inv cf IFRSCurrentYTDDuration237000000JPY
Proceeds from sale or redemption of financial assets measured at amortised cost inv cf IFRSPrior1YTDDuration1000000000JPY
Proceeds from sale or redemption of financial assets measured at amortised cost inv cf IFRSCurrentYTDDuration1400000000JPY
Purchase of property plant and equipment inv cf IFRSPrior1YTDDuration-1196000000JPY
Purchase of property plant and equipment inv cf IFRSCurrentYTDDuration-2572000000JPY
Purchase of intangible assets inv cf IFRSPrior1YTDDuration-1085000000JPY
Purchase of intangible assets inv cf IFRSCurrentYTDDuration-1228000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-10-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2021-10-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass